Silencing KRAS overexpression in arsenic-transformed prostate epithelial and stem cells partially mitigates malignant phenotype

Toxicological Sciences

Volumn 142, Issue 2, 2014, Pages 489-496

  Ngalame, Ntube N O ^a   Tokar, Erik J ^a   Person, Rachel J ^a   Waalkes, Michael P ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Arsenic; Cancer; Kras; Prostate cells; Shrna; Stem cells

Indexed keywords

ARSENIC; CYCLIN D1; GELATINASE B; PROTEIN P16; PROTEIN P21; ARSENITE SODIUM; ARSENOUS ACID DERIVATIVE; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; SMALL INTERFERING RNA; SODIUM DERIVATIVE;

ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; COLONY FORMING CELL; CONTROLLED STUDY; ENZYME ACTIVITY; GENE ACTIVATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; NONHUMAN; ONCOGENE K RAS; PHENOTYPE; PROSTATE EPITHELIUM CELL; PROSTATE STEM CELL; RNA INTERFERENCE; STEM CELL; TUMOR GROWTH; ANIMAL; CANCER STEM CELL; CELL MOTION; CELL TRANSFORMATION; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG SCREENING; EPITHELIUM CELL; GENETICS; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATE; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; ARSENITES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; MALE; MICE, NUDE; NEOPLASTIC STEM CELLS; PROSTATE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SODIUM COMPOUNDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922428067     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfu201     Document Type: Article

References (36)

1. Achanzar, W. E., Brambila, E. M., Diwan, B. A., Webber, M. M., and Waalkes, M. P. (2002). Inorganic arsenite-induced malignant transformation of human prostate epithelial cells. J. Natl Cancer Inst. 94, 1888-1891.
2. Bachmeier, B. E., Boukamp, P., Lichtinghagen, R., Fusenig, N. E., and Fink, E. (2000). Matrix metalloproteinases-2,-3,-7,-9 and-10, but not MMP-11, are differentially expressed in normal, benign tumorigenic and malignant human keratinocyte cell lines. Biol. Chem. 381, 497-507.
3. Bartel, D. P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297.
4. Bello, D., Webber, M. M., Kleinman, H. K., Wartinger, D. D., and Rhim, J. S. (1997). Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 18, 1215-1223.
5. Benbrahim-Tallaa, L., and Waalkes, M. P. (2008). Inorganic arsenic and human prostate cancer. Environ. Health Perspect. 116, 158-164.
6. Benbrahim-Tallaa, L., Waterland, R. A., Styblo, M., Achanzar, W. E., Webber, M. M., and Waalkes, M. P. (2005). Molecular events associated with arsenic-induced malignant transformation of human prostatic epithelial cells: aberrant genomic DNA methylation and K-ras oncogene activation. Toxicol. Appl. Pharmacol. 206, 288-298.
7. Boll, K., Reiche, K., Kasack, K., Morbt, N., Kretzschmar, A. K., Tomm, J. M., Verhaegh, G., Schalken, J., von Bergen, M., and Horn, F. (2013). MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene 32, 277-285.
8. Brummelkamp, T. R., Bernards, R., and Agami, R. (2002). Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2, 243-247.
9. Chen, H., Liu, J., Merrick, B. A., and Waalkes, M. P. (2001). Genetic events associated with arsenic-induced malignant transformation: applications of cDNA microarray technology. Mol. Carcinog. 30, 79-87.
10. Downward, J. (2003). Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3, 11-22.
11. Fleming, J. B., Shen, G. L., Holloway, S. E., Davis, M., and Brekken, R. A. (2005). Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Mol. Cancer Res. 3, 413-423.
12. Grossmann, M., Cheung, A. S., and Zajac, J. D. (2013). Androgens and prostate cancer; pathogenesis and deprivation therapy. Best Pract. Res. Clin. Endocrinol. Metab. 27, 603-616.
13. Hagman, Z., Haflidadottir, B. S., Ceder, J. A., Larne, O., Bjartell, A., Lilja, H., Edsjo, A., and Ceder, Y. (2013). miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients. Br. J. Cancer 108, 1668-1676.
14. Hanahan, D., and Weinberg, R. A. (2000). The hallmarks of cancer. Cell 100, 57-70.
15. IARC. (2012). (International Agency for Research on Cancer) Arsenic and arsenic compounds. IARC Monogr. Eval. Carcinog. Risk Hum. 100C, 41-94.
16. Jemal, A., Thomas, A., Murray, T., and Thun, M. (2002). Cancer statistics, 2002. CA Cancer J. Clin. 52, 23-47.
17. Karnoub, A. E., and Weinberg, R. A. (2008). Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol. 9, 517-531.
18. Kessenbrock, K., Plaks, V., and Werb, Z. (2010). Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52-67.
19. Liu, C., Kelnar, K., Vlassov, A. V., Brown, D., Wang, J., and Tang, D. G. (2012). Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7. Cancer Res. 72, 3393-3404.
20. Moul, J. W., Friedrichs, P. A., Lance, R. S., Theune, S. M., and Chang, E. H. (1992). Infrequent RAS oncogene mutations in human prostate cancer. Prostate 20, 327-338.
21. Ngalame, N. N., Tokar, E. J., Person, R. J., Xu, Y., and Waalkes, M. P. (2014). Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic. Toxicol. Sci. 138, 268-277.
22. Noel, A., Jost, M., and Maquoi, E. (2008). Matrix metalloproteinases at cancer tumor-host interface. Semin. Cell Dev. Biol. 19, 52-60.
23. Okoji, R. S., Yu, R. C., Maronpot, R. R., and Froines, J. R. (2002). Sodium arsenite administration via drinking water increases genome-wide and Ha-ras DNA hypomethylation in methyl-deficient C57BL/6J mice. Carcinogenesis 23, 777-785.
24. Ostling, P., Leivonen, S. K., Aakula, A., Kohonen, P., Makela, R., Hagman, Z., Edsjo, A., Kangaspeska, S., Edgren, H., Nicorici, D., et al. (2011). Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res. 71, 1956-1967.
25. Pi, J., Diwan, B. A., Sun, Y., Liu, J., Qu, W., He, Y., Styblo, M., and Waalkes, M. P. (2008). Arsenic-induced malignant transformation of human keratinocytes: involvement of Nrf2. Free Radic. Biol. Med. 45, 651-658.
26. Radisky, E. S., and Radisky, D. C. (2010). Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J. Mammary Gland Biol. Neoplasia 15, 201-212.
27. Shi, X. H., Liang, Z. Y., Ren, X. Y., and Liu, T. H. (2009). Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo. Cancer Gene Ther. 16, 227-236.
28. Siegel, R., Ma, J., Zou, Z., and Jemal, A. (2014). Cancer statistics, 2014. CA Cancer J. Clin. 64, 9-29.
29. Silan, F., Gultekin, Y., Atik, S., Kilinc, D., Alan, C., Yildiz, F., Uludag, A., and Ozdemir, O. (2012). Combined point mutations in codon 12 and 13 of KRAS oncogene in prostate carcinomas. Mol. Biol. Rep. 39, 1595-1599.
30. Smakman, N., Veenendaal, L. M., van Diest, P., Bos, R., Offringa, R., Borel Rinkes, I. H., and Kranenburg, O. (2005). Dual effect of Kras(D12) knockdown on tumorigenesis: increased immune-mediated tumor clearance and abrogation of tumor malignancy. Oncogene 24, 8338-8342.
31. Stetler-Stevenson, W. G., Hewitt, R., and Corcoran, M. (1996). Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin. Cancer Biol. 7, 147-154.
32. Stingl, J., Eirew, P., Ricketson, I., Shackleton, M., Vaillant, F., Choi, D., Li, H. I., and Eaves, C. J. (2006). Purification and unique properties of mammary epithelial stem cells. Nature 439, 993-997.
33. Sunaga, N., Shames, D. S., Girard, L., Peyton, M., Larsen, J. E., Imai, H., Soh, J., Sato, M., Yanagitani, N., Kaira, K., et al. (2011). Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol. Cancer Ther. 10, 336-346.
34. Tokar, E. J., Ancrile, B. B., Cunha, G. R., and Webber, M. M. (2005). Stem/progenitor and intermediate cell types and the origin of human prostate cancer. Differentiation 73, 463-473.
35. Tokar, E. J., Diwan, B. A., and Waalkes, M. P. (2010). Arsenic exposure transforms human epithelial stem/progenitor cells into a cancer stem-like phenotype. Environ. Health Perspect. 118, 108-115.
36. Zorde Khvalevsky, E., Gabai, R., Rachmut, I. H., Horwitz, E., Brunschwig, Z., Orbach, A., Shemi, A., Golan, T., Domb, A. J., Yavin, E., et al. (2013). Mutant KRAS is a druggable target for pancreatic cancer. Proc. Natl Acad. Sci. U. S. A. 110, 20723-20728.